Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
